SVRA vs. SLN, ZYME, LYEL, MLYS, PHAR, AVBP, ORIC, PHAT, STOK, and CALT
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Silence Therapeutics (SLN), Zymeworks (ZYME), Lyell Immunopharma (LYEL), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Silence Therapeutics (NASDAQ:SLN) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Savara has a net margin of 0.00% compared to Savara's net margin of -131.44%. Silence Therapeutics' return on equity of -51.95% beat Savara's return on equity.
Silence Therapeutics currently has a consensus price target of $57.25, indicating a potential upside of 148.91%. Savara has a consensus price target of $8.80, indicating a potential upside of 96.43%. Given Savara's higher probable upside, equities analysts plainly believe Silence Therapeutics is more favorable than Savara.
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 4.6% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Silence Therapeutics has higher revenue and earnings than Savara. Silence Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
Savara received 264 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Silence Therapeutics an outperform vote while only 65.98% of users gave Savara an outperform vote.
In the previous week, Savara had 10 more articles in the media than Silence Therapeutics. MarketBeat recorded 18 mentions for Savara and 8 mentions for Silence Therapeutics. Savara's average media sentiment score of 0.69 beat Silence Therapeutics' score of -0.04 indicating that Silence Therapeutics is being referred to more favorably in the media.
Silence Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Summary
Silence Therapeutics and Savara tied by winning 8 of the 16 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
